Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 16/20 | 0.88 |
| ▸ | BCL2 | P10415 | 12/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.54 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542046 | 0.97 | BCL2L1 (0.89) | BCL2L1BCL2SMN1; SMN2BDKRB1ALB | |
| SCHEMBL27671268 | 0.97 | BCL2L1 (0.89) | BCL2L1BCL2SMN1; SMN2BDKRB1ALB | |
| SCHEMBL554723 | 0.94 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL29686481 | 0.94 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL376632 | 0.94 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL4733552 | 0.89 | BCL2L1 (0.88) | BCL2L1BCL2ALBBCL2L2DOT1L | |
| SCHEMBL2945774 | 0.88 | BCL2L1 (0.82) | BCL2L1BCL2SMN1; SMN2BDKRB1ALB | |
| SCHEMBL1542094 | 0.87 | BCL2L1 (0.70) | BCL2L1BCL2ALBBCL2L2DOT1L | |
| SCHEMBL2027016 | 0.87 | BCL2L1 (0.70) | BCL2L1BCL2ALBBCL2L2DOT1L | |
| SCHEMBL2021922 | 0.87 | BCL2L1 (0.81) | BCL2L1BCL2SMN1; SMN2BDKRB1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-7030115-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2003-12-25 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885SMN1; SMN2 1440/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885SMN1; SMN2 2412/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885SMN1; SMN2 1656/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885SMN1; SMN2 1440/4885 |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, BAD | BCL2L1 13/4885BCL2 2/4885SMN1; SMN2 328/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885SMN1; SMN2 2412/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | BCL2L1 20/4885BCL2 4/4885SMN1; SMN2 1110/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885SMN1; SMN2 2412/4885 |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, AIFM1 | BCL2L1 9/4885BCL2 2/4885SMN1; SMN2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.